Join Growin Stock Community!

Skye bioscience, inc.SKYE.US Overview

US StockHealthcare
(No presentation for SKYE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SKYE AI Insights

SKYE Overall Performance

SKYE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SKYE Recent Performance

2.79%

Skye bioscience, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SKYE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SKYE Key Information

SKYE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SKYE Profile

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.

Price of SKYE

SKYE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SKYE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.73
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.73
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is SKYE's latest earnings report released?

    The most recent financial report for Skye bioscience, inc. (SKYE) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SKYE's short-term business performance and financial health. For the latest updates on SKYE's earnings releases, visit this page regularly.

  • How much debt does SKYE have?

    As of the end of the reporting period, Skye bioscience, inc. (SKYE) had total debt of 321.85K, with a debt ratio of 0.01. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SKYE have?

    At the end of the period, Skye bioscience, inc. (SKYE) held Total Cash and Cash Equivalents of 18.44M, accounting for 0.45 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SKYE's EPS continuing to grow?

    According to the past four quarterly reports, Skye bioscience, inc. (SKYE)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SKYE?

    Skye bioscience, inc. (SKYE)'s Free Cash Flow (FCF) for the period is -13.36M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 97.08% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.